Human FGA ELISA Matched Antibody Pair (ABPR-0333)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Species Reactivity
Human
Intended Use
This antibody pair set comes with matched antibody pair to detect and quantify protein level of human FGA.
General Description
The protein encoded by this gene is the alpha component of fibrinogen, a blood-borne glycoprotein comprised of three pairs of nonidentical polypeptide chains. Following vascular injury, fibrinogen is cleaved by thrombin to form fibrin which is the most abundant component of blood clots. In addition, various cleavage products of fibrinogen and fibrin regulate cell adhesion and spreading, display vasoconstrictor and chemotactic activities, and are mitogens for several cell types. Mutations in this gene lead to several disorders, including dysfibrinogenemia, hypofibrinogenemia, afibrinogenemia and renal amyloidosis. Alternative splicing results in two isoforms which vary in the carboxy-terminus.
Reconstitution And Storage
Store reagents of the antibody pair set at -20°C or lower. Please aliquot to avoid repeated freeze thaw cycle. Reagents should be returned to -20°C storage immediately after use.

Citations


Have you cited ABPR-0333 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


A large-scale exome array analysis of venous thromboembolism

GENETIC EPIDEMIOLOGY

Authors: Lindstrom, Sara; Brody, Jennifer A.; Turman, Constance; Germain, Marine; Bartz, Traci M.; Smith, Erin N.; Chen, Ming-Huei; Puurunen, Marja; Chasman, Daniel; Hassler, Jeffrey; Pankratz, Nathan; Basu, Saonli; Guan, Weihua; Gyorgy, Beata; Ibrahim, Manal; Empana, Jean-Philippe; Olaso, Robert; Jackson, Rebecca; Braekkan, Sigrid K.; McKnight, Barbara; Deleuze, Jean-Francois; O'Donnell, Cristopher J.; Jouven, Xavier; Frazer, Kelly A.; Psary, Bruce M.; Wiggins, Kerri L.; Taylor, Kent; Reiner, Alexander P.; Heckbert, Susan R.; Kooperberg, Charles; Ridker, Paul; Hansen, John-Bjarne; Tang, Weihong; Johnson, Andrew D.; Morange, Pierre-Emmanuel; Tregouet, David A.; Kraft, Peter; Smith, Nicholas L.; Kabrhel, Christopher

Although recent Genome-Wide Association Studies have identified novel associations for common variants, there has been no comprehensive exome-wide search for low-frequency variants that affect the risk of venous thromboembolism (VTE). We conducted a meta-analysis of 11 studies comprising 8,332 cases and 16,087 controls of European ancestry and 382 cases and 1,476 controls of African American ancestry genotyped with the Illumina HumanExome BeadChip. We used the seqMeta package in R to conduct single variant and gene-based rare variant tests. In the single variant analysis, we limited our analysis to the 64,794 variants with at least 40 minor alleles across studies (minor allele frequency [MAF] similar to 0.08%). We confirmed associations with previously identified VTE loci, including ABO, F5, F11, and FGA. After adjusting for multiple testing, we observed no novel significant findings in single variant or gene-based analysis. Given our sample size, we had greater than 80% power to detect minimum odds ratios greater than 1.5 and 1.8 for a single variant with MAF of 0.01 and 0.005, respectively. Larger studies and sequence data may be needed to identify novel low-frequency and rare variants associated with VTE risk.

Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region

ASIA-PACIFIC PSYCHIATRY

Authors: Tang, Chao Tian; Chua, Ee Cheong; Chew, Qian Hui; He, Yan-Ling; Si, Tian-Mei; Chiu, Helen F-K; Xiang, Yu-Tao; Kato, Takahiro A.; Kanba, Shigenobu; Shinfuku, Naotaka; Lee, Min-Soo; Park, Seon-Cheol; Park, Yong-Chon; Chong, Mian-Yoon; Lin, Shih-Ku; Yang, Shu-Yu; Tripathi, Adarsh; Avasthi, Ajit; Grover, Sandeep; Kallivayalil, Roy A.; Udomratn, Pichet; Chee, Kok Yoon; Tanra, Andi J.; Rabbani, Md Golam; Javed, Afzal; Kathiarachchi, Samudra; Waas, Dulshika; Myint, Wing Aung; Sartorius, Norman; Van Cuong Tran; Kim Viet Nguyen; Tan, Chay-Hoon; Baldessarini, Ross J.; Sim, Kang

Introduction Patterns of clinical use of long-acting injectable (LAI) antipsychotic drugs in many countries, especially in Asia, for treatment of patients diagnosed with chronic psychotic disorders including schizophrenia are not well established. Methods Within an extensive research consortium, we evaluated prescription rates for first- (FGA) and second-generation antipsychotic (SGA) LAI drugs and their clinical correlates among 3557 subjects diagnosed with schizophrenia across 15 Asian countries and region. Results Overall, an average of 17.9% (638/3557; range: 0.0%-44.9%) of treated subjects were prescribed LAI antipsychotics. Those given LAI vs orally administered agents were significantly older, had multiple hospitalizations, received multiple antipsychotics more often, at 32.4% higher doses, were more likely to manifest disorganized behavior or aggression, had somewhat superior psychosocial functioning and less negative symptoms, but were more likely to be hospitalized, with higher BMI, and more tremor. Being prescribed an FGA vs SGA LAI agent was associated with male sex, aggression, disorganization, hospitalization, multiple antipsychotics, higher doses, with similar risks of adverse neurological or metabolic effects. Rates of use of LAI antipsychotic drugs to treat patients diagnosed with schizophrenia varied by more than 40-fold among Asian countries and given to an average of 17.9% of treated schizophrenia patients. We identified the differences in the clinical profiles and treatment characteristics of patients who were receiving FGA-LAI and SGA-LAI medications. Discussion These findings behoove clinicians to be mindful when evaluating patients' need to be on LAI antipsychotics amidst multifaceted considerations, especially downstream adverse events such as metabolic and extrapyramidal side effects.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket